# ANTI-TAC THERAPY FOR UVEITIS

> **NCT00001526** · PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 15 (—)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** Daclizumab (Zenapax)

## Key facts

- **NCT ID:** NCT00001526
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-06-04
- **Primary completion:** —
- **Final completion:** 2007-09-06
- **Target enrollment:** 15 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001526, "ANTI-TAC THERAPY FOR UVEITIS". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00001526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*